TrialCancer2026

Neoadjuvant chemotherapy for soft-tissue sarcoma of the extremities: A post-hoc Sarculator-based risk analysis of the EORTC 62961-ESHO 95 randomized trial.

Markus Albertsmeier et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.